Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia

  • Daniel WeisdorfEmail author
  • Stephen Forman
Part of the Cancer Treatment and Research book series (CTAR, volume 144)


Although multidrug chemotherapy yields complete remission (CR) for nearly 90% of adults with acute lymphoblastic leukemia (ALL, a.k.a. acute lymphocytic leukemia), post-remission therapy fails to control disease recurrence for the majority [1, 2, 3, 4, 5, 6, 7, 8]. Twenty percent of adult acute leukemia is ALL, and despite some parallels to the morphology and molecular features of pediatric ALL, where therapy is often curative [9, 10, 11, 12], the majority of adults have high-risk phenotypes of disease, and current therapies remain inadequate. Extended leukemia-free survival (LFS) in unlikely, particularly for those with high-risk features including age greater than 35 years, elevated white blood count (WBC) at diagnosis, cytogenetically high-risk subsets and poor initial response to therapy. These further truncate the odds of extended LFS. Newer immunopathologic, molecular and monitoring techniques have improved classifications and potentially allowed risk-directed...


Acute Lymphoblastic Leukemia Hematopoietic Stem Cell Transplantation Minimal Residual Disease Total Body Irradiation Allogeneic Hematopoietic Stem Cell Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gökbuget N, Noelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006;133–41.Google Scholar
  2. 2.
    Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Goldstone AH, Richards SH, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplant is less effective than conventional consolidation maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111:1827–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;54:166–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16:1259–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025–37.PubMedGoogle Scholar
  7. 7.
    Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123–31.PubMedGoogle Scholar
  8. 8.
    Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL BFM90: German-Austrian Swiss ALL BFM Study Group. Blood 2000;95:3310–22.PubMedGoogle Scholar
  10. 10.
    Silverman LB, Gelber RD, Dalton VK, et al. Approved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium protocol 91-01. Blood 2001;97:1211–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukemia. MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998;12:463–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol. 1997;24:3–16.PubMedGoogle Scholar
  14. 14.
    Sali D, Cardis E, Sztanyik L, et al. Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Int J Cancer. 1996;67:343–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 2000;355:165–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrando AA, Look AT. Pathobiology of acute lymphoblastic leukemia. In: Hoffman, R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology. Basic principles and practices, 4th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 1135–54.Google Scholar
  17. 17.
    Pullarkat VA, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group study SWOG-9400. Blood 2008;111:2563–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–407.PubMedCrossRefGoogle Scholar
  20. 20.
    Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108:1469–77.PubMedCrossRefGoogle Scholar
  21. 21.
    Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2007;109:2068–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449–57.PubMedCrossRefGoogle Scholar
  24. 24.
    Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791–3.PubMedGoogle Scholar
  25. 25.
    Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101: 2788–801.PubMedCrossRefGoogle Scholar
  26. 26.
    Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094–104.PubMedCrossRefGoogle Scholar
  27. 27.
    Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116–23.PubMedCrossRefGoogle Scholar
  28. 28.
    Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007;109:910–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007;21:622–6.PubMedGoogle Scholar
  30. 30.
    Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028–37.PubMedCrossRefGoogle Scholar
  32. 32.
    Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA87. Hematol Oncol Clin North Am. 2000;14:1353–66.PubMedCrossRefGoogle Scholar
  33. 33.
    Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in relation compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106:2657–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86:1619–28.PubMedGoogle Scholar
  36. 36.
    Thiebaut A, Vernanr JP, Degos L, Huguet FR, Reiffers J, Debban C, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000;14:1353–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G, et al., EORTC Leukemia Group. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica 2004;89:809–17.PubMedGoogle Scholar
  38. 38.
    Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol. 2002;20:4655–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant. 2004;33:397–404.PubMedCrossRefGoogle Scholar
  40. 40.
    Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant. 1991;7:453–9.PubMedGoogle Scholar
  41. 41.
    Blume KG, Forman SJ, Snyder DS, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation. 1987;43:389–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Vernant JP, Marit G, Maraninchi D, et al. Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission. J Clin Oncol. 1988;6:227–31.PubMedGoogle Scholar
  43. 43.
    Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol. 1994;12:2580–7.PubMedGoogle Scholar
  44. 44.
    Vey N, Blaise D, Stoppa AM, et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 1994;14:383–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Marks DI, Perez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112:426–34.Google Scholar
  46. 46.
    Bachanova V, Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant. 2008;41:455–64PubMedCrossRefGoogle Scholar
  47. 47.
    Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8:213–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Barker JN, Weisdorf D, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med. 2001;24:1870–81.CrossRefGoogle Scholar
  50. 50.
    Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006;38:421–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Bishop MR, Logan BR, Gandham S, et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 41:635–42.Google Scholar
  52. 52.
    Garderet L, Labopin M, Gorin NC, Polge E, Fouillard L, Ehringer GE, et al. Patients with acute lymphoblastic leukemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant. 2003;31:23–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Dahlke J, Kröger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37:155–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.PubMedCrossRefGoogle Scholar
  55. 55.
    Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.PubMedCrossRefGoogle Scholar
  56. 56.
    Cornetta K, Laughlin M, Carter S, Wall D, Weinthal J, Delaney C, et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant. 2005;11:149–60.PubMedCrossRefGoogle Scholar
  57. 57.
    Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004;104:3813–20.PubMedCrossRefGoogle Scholar
  58. 58.
    Tomblyn MB, DeFor TE, Tomblyn MR, MacMillan M, Higgins PD, Dusenbery KE, et al. Hematopoietic cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL): 25-year experience at the University of Minnesota. J Clin Oncol. 2007;25(Suppl 185):3575.Google Scholar
  59. 59.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.PubMedGoogle Scholar
  60. 60.
    Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia 1997;11:S15–S17.PubMedGoogle Scholar
  61. 61.
    Weisdorf DJ, Nesbit ME, Ramsay NKC, Woods WG, Goldman A, Kim TH, Hurd DD, McGlave PB, Kersey JH: Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft vs. host disease. J Clin Oncol. 1987;5:1348–55.PubMedGoogle Scholar
  62. 62.
    Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21:153–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041–50.PubMedGoogle Scholar
  64. 64.
    Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–44.PubMedGoogle Scholar
  65. 65.
    Valcarcel D, Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol. 2005;74:144–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Arnold R, Massenkeil G, Bornhäuser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002;16:2423–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodriguez OG, et al. Non-myeloablative stem cell transplantation in patients with relapsed cute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant. 2007;40:535–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernández-Avilés F, San Miguel J, Sierra J. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003;88:555–60.PubMedGoogle Scholar
  69. 69.
    Stein A, O’Donnell M, Snyder D, et al. Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2007;13:134.CrossRefGoogle Scholar
  70. 70.
    Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V; Acute Leukemia Working Party; European Group for Blood and Marrow Transplantation. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008;93:303–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a South-West Oncology Group study. Blood 1993;81:2187–93.PubMedGoogle Scholar
  72. 72.
    Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12:438–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237–47.PubMedGoogle Scholar
  74. 74.
    Wong JY, Liu A, Schultheiss T, et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant. 2006;12:306–15.PubMedCrossRefGoogle Scholar
  75. 75.
    Lee SJ, Klein JP, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.University of Minnesota, Mayo Mail Code 480MinneapolisUSA

Personalised recommendations